Medicare Cancer Rx Payments Will Be “Disastrous,” Ex-ASCO Head Warns
Executive Summary
Oncology drug reimbursement changes mandated by the 2003 Medicare Rx law will cause long term damage to patient care, Memorial Sloan-Kettering Director of Breast Cancer Programs Larry Norton, MD, said June 22 at a Newsweek/Coalition of National Cancer Cooperative Groups panel in Washington, D.C
You may also be interested in...
Medicare Part B ASP Rates Meet Physician Costs For Most Drugs, OIG Finds
Oncologists and hematologists continue to be able to purchase most drugs for use in outpatient settings at prices below the Medicare Part B reimbursement rate, even with Medicare's switch to payment at 106% of average sales price, an HHS Office of Inspector General audit found
Medicare Part B ASP Rates Meet Physician Costs For Most Drugs, OIG Finds
Oncologists and hematologists continue to be able to purchase most drugs for use in outpatient settings at prices below the Medicare Part B reimbursement rate, even with Medicare's switch to payment at 106% of average sales price, an HHS Office of Inspector General audit found
Inhalation Rx Market In Transition; CMS May Increase 2005 Payments
The Center for Medicare & Medicaid Services is inviting comment on how best to manage the transition of the inhalation therapy market ahead of the outpatient Medicare prescription drug benefit beginning in 2006